Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
RXRX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsRecursion Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.07B, an increase of 26.92% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | +$0.02B | +26.92% |
| 2024-12-31 | $0.06B | +$0.01B | +34.10% |
| 2023-12-31 | $0.04B | +$0.00B | +10.57% |
| 2022-12-31 | $0.04B | +$0.03B | +296.81% |
| 2021-12-31 | $0.01B | +$0.01B | +193.00% |
| 2020-12-31 | $0.00B | +$0.00B | +99.47% |
| 2019-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare RXRX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Recursion Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Recursion Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Recursion Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RXRX revenue · 4 questionsRXRX's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 26.92% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Recursion Pharmaceuticals, Inc. SEC filings · GAAP · Recursion Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026